Prostate specific antigen velocity as a measure of the natural history of prostate cancer: Defining a 'rapid riser' subset

British Journal of Urology

Volumn 81, Issue 1, 1998, Pages 100-104

  Nam, R K ^a   Klutz, L H ^a   Jewett, M A S ^a   Danjoux, C ^a   Trachtenberg, J ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Natural history; Prostate cancer; Prostate specific antigen; PSA velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONSERVATIVE TREATMENT; DISEASE ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0031870063     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00523.x     Document Type: Article

References (16)

1. Chodak GW. Thisted RA. Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 350: 242-8
2. Rosen MA. Impact of prostate specific antigen screening on the natural history of prostate cancer, Urology 1995; 46: 757-68 5 Schellhammer PF. Fahozzi S. Natural history of prostate cancer: an analysis of contemporary expectant therapy series. Adv Urol 1995; 8: 1-20
3. Johansson J-E. Adami H-O. Andersson S-O. Bergstrom R. Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992: 267: 2191-6
4. Aus G. Hugosson J. Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Ural 1995: 154: 460-5
5. Albertsen PC. Fryback DC,. Storer BF. Kolon TF. Fine . Longterm survival among men with conservatively treated localized prostate cancer. JAMA 1995: 274: 626-51
6. Carter HB, Pearson JI). Metter J et al Natural history of changes in prostate specific antigen in early stage prostate cancer. J U ml 1994: 152: 1745-8
7. Kalish J. Cooner WH. Graham SD. Serum PSA adjusted for volume of transition zone IPSAT) is more accurate than PSA adjusted for total gland volume (PSADl in detecting adenocarcinoma of the prostate. Urology 1994: 43: 601-6
8. Partin AW. Yoo ). Carter HB et ni. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J L'i-o/ 1995: 150: 1 10-4
9. Lerner SE. Seay TM. Blute ML. Bergstralh EJ. Barrel! D. Zincke H. Prostate specific antigen detected prostate cancer (clinical stage TIC): an interim analysis. J Lirol 1996: 155: 821-6
10. Schmid H-P. McNeal JE. Stanley TA. Observations on thedoubling time of prostate cancer. Cancer 1995: 71: 2051-40
11. Stamey TA, Yang N. Hay AR, McNeal JE. Freiha FS. Redwine E. Prostate-specific antigen as a scrum marker for adenocarcinoma of the prostate. \I-lngl J Med 1987: 317: 909-15
12. 5 Cann PH. Hennekens CH. Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostalic cancer. AMA 1995: 273: 289-94
13. El-Galley RES. Petras JA. Sanders VVH et al Normal range prostate-specific antigen versus age- specific prostate-specific antigen in screening prostate adenocarcinoma. Urology 1995; 46: 200-4
14. Roehrborn CG. Pickens GJ. Carmody III T. Variability of repeated serum prostate specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology 1996; 47: 59-66
15. Lee RW. Hanks GE. Corn BW. Schultheiss TE. Observations of pretreatment prostate specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int }Rad Oncol Biol Phijs 1995: 31: 21-4
16. Hanks GE. D'Amico A, Epstein BE. Schultheiss TE. Prostatic specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. M ) Rad Oncol Biol Phys 1993: 27: 125-7